Articles By Anuja Singh
GSK Bets on Cambridge: Inside the R&D Push Behind a £40 Billion Sales Target
A look at GSK’s new Cambridge research centre, its cost-cutting programme, and what a 75% profit drop tells…
By
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means…
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Novartis’s U.S. Pricing Reckoning: How Generic Erosion and Growth-Brand Volume Are Reshaping the Post-Entresto…
Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and what it signals…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound…
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
With the Only FDA-Cleared Blood Test for Alzheimer’s Risk, Can Roche’s ADLM 2026 Portfolio…
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026 reflects a clear…
GSK Bets on Cambridge: Inside the R&D Push Behind a £40 Billion Sales Target
A look at GSK’s new Cambridge research centre, its cost-cutting programme, and what a 75% profit drop tells…
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means…
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Novartis’s U.S. Pricing Reckoning: How Generic Erosion and Growth-Brand Volume Are Reshaping the Post-Entresto…
Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and what it signals…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound…
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
With the Only FDA-Cleared Blood Test for Alzheimer’s Risk, Can Roche’s ADLM 2026 Portfolio…
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026 reflects a clear…